Middle East And Africa Circulating Tumor Cells Ctc Liquid Biopsy Market
حجم السوق بالمليار دولار أمريكي
CAGR : %
فترة التنبؤ |
2022 –2029 |
حجم السوق (السنة الأساسية) |
USD 24.50 Million |
حجم السوق (سنة التنبؤ) |
USD 82.24 Million |
CAGR |
|
Major Markets Players |
>سوق خزعة الخلايا السرطانية المتداولة (CTC) السائلة في الشرق الأوسط وأفريقيا، حسب التكنولوجيا (طرق اكتشاف CTC، وطرق إثراء CTC، والاختيار الإيجابي خارج الجسم الحي، والتكنولوجيات القائمة على الجزيئات (RNA)، واختبار غزو الخلايا الوظيفية في المختبر، ونماذج زراعة الأعضاء الغريبة، والرقائق الدقيقة، والقنوات الدقيقة الحلزونية المفردة، والاختيار السلبي وتقنيات الكيمياء المناعية الخلوية)، والتطبيق (أبحاث الخلايا الجذعية السرطانية، وتشوهات الكروموسومات المتعددة وغيرها)، والمستخدم النهائي (المعاهد البحثية والأكاديمية، والمختبرات المرجعية والمستشفيات ومختبرات الأطباء)، والدولة (جنوب أفريقيا والمملكة العربية السعودية والإمارات العربية المتحدة ومصر والكويت وإسرائيل وبقية دول الشرق الأوسط وأفريقيا) - اتجاهات الصناعة والتوقعات -2029
تحليل السوق والرؤى: سوق خزعة الخلايا السرطانية المتداولة (CTC) السائلة في الشرق الأوسط وأفريقيا
من المتوقع أن يكتسب سوق خزعة الخلايا السرطانية المتداولة (CTC) في الشرق الأوسط وأفريقيا نموًا في السوق في الفترة المتوقعة من 2022 إلى 2029. تحلل Data Bridge Market Research أن السوق ينمو بمعدل نمو سنوي مركب بنسبة 16.7٪ في الفترة المتوقعة من 2022 إلى 2029 ومن المتوقع أن يصل إلى 82.24 مليون دولار أمريكي بحلول عام 2029 من 24.50 مليون دولار أمريكي في عام 2021. من المرجح أن يكون ارتفاع معدل انتشار الأمراض المزمنة وزيادة أنشطة البحث والتطوير لتطبيقها الفعال من المحركات الرئيسية التي تدفع الطلب على السوق في الفترة المتوقعة.
الخزعة السائلة هي اختبار دم غير جراحي يكتشف الخلايا السرطانية المنتشرة وشظايا الحمض النووي للورم والتي يتم إطلاقها في الدم من الأورام الأولية والمواقع النقيلية. إنها بديل بسيط ودقيق لإجراء الخزعة الجراحية، مما يسمح للجراح باكتشاف السرطان في مرحلة مبكرة للغاية.
الخلايا السرطانية المنتشرة هي مجموعة فرعية نادرة من الخلايا التي تعمل كبذرة للنقائل. توجد في دم المرضى الذين أصيبوا بأورام صلبة. يسمح اختبار الخلايا السرطانية المنتشرة باكتشاف وتحديد كمية الخلايا السرطانية في دم مرضى السرطان. تشمل الأنواع المختلفة من النمط الظاهري البيولوجي للخلايا السرطانية المنتشرة (CTCs) الخلايا الجذعية الشبيهة أو المختلطة أو المتوسطة أو الظهارية. توجد هذه الأنماط الظاهرية في الدم بكميات صغيرة جدًا. ونتيجة لذلك، يحتاج اكتشافها إلى مرحلة عزل وإثراء. بعد ذلك، مرحلة ثانية من الكشف.
الطلب المتزايد على خزعة الخلايا السرطانية المتداولة (CTC) السائلة بسبب فعاليتها، وارتفاع معدل انتشار السرطان هي المحركات الرئيسية التي تدفع الطلب على سوق خزعة الخلايا السرطانية المتداولة (CTC) السائلة (CTC) في فترة التنبؤ. ومع ذلك، فإن السيناريو التنظيمي والتعويض غير الواضح، ونقص الموظفين المهرة يقيد نمو سوق خزعة الخلايا السرطانية المتداولة (CTC) السائلة (CTC) في فترة التنبؤ.
The Middle East and Africa circulating tumor cells (CTC) liquid biopsy market report provides details of market share, new developments, and impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario, contact us for an Analyst Brief. Our team will help you create a revenue impact solution to achieve your desired goal.
Middle East and Africa Circulating Tumor Cells (CTC) Liquid Biopsy Market Scope and Market Size
Middle East and Africa circulating tumor cells (CTC) liquid biopsy market is categorized into three notable segments which are based on technology, application and end user. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of technology, circulating tumor cells (CTC) liquid biopsy market is segmented into CTC detection methods, CTC enrichment methods, ex vivo positive selection, molecular (RNA)-based technologies, functional in vitro cell invasion assay, xenotransplantation methods, microchips, single spiral microchannel, negative selection and immunocytochemical technologies In 2021, CTC detection methods segment is expected to dominate the market because of increasing use of this technology in the academics and research centers for the tests of liquid biopsy.
- On the basis of application, circulating tumor cells (CTC) liquid biopsy market is segmented into cancer stem cell research, multiple chromosome abnormalities and others. In 2021, cancer stem cell research segment is expected to dominate the market because of increasing demand of early diagnosis and treatment of cancer.
- On the basis of end user, circulating tumor cells (CTC) liquid biopsy market is segmented into research and academic institutes, reference laboratories and hospitals and physician laboratories. In 2021, academic and research institutes segment is expected to dominate the market because of research and academic institutes perform an essential role to accelerate research and development in the various therapeutic area related to liquid biopsies.
Middle East and Africa Circulating Tumor Cells (CTC) Liquid Biopsy Market Country Level Analysis
The Middle East and Africa circulating tumor cells (CTC) liquid biopsy market is analysed and market size information is provided by country, technology, application and end user.
The countries covered in the Middle East and Africa circulating tumor cells (CTC) liquid biopsy market report are South Africa, Saudi Arabia, UAE, Egypt, Kuwait, Israel and Rest of the Middle East and Africa.
South Africa is expected to dominate the market because of high prevalence of chronic diseases such as cancer and increasing disposable income.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Middle East and Africa brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of sales channels are considered while providing forecast analysis of the country data.
The Presence of Advanced Technology and Strategic Initiatives Taken by Players are Creating New Opportunities in Middle East and Africa Circulating Tumor Cells (CTC) Liquid Biopsy Market
Middle East and Africa circulating tumor cells (CTC) liquid biopsy market also provides you with detailed market analysis for every country's growth in a particular industry with products sales, the impact of advancement in the market, and changes in regulatory scenarios with their support for the circulating tumor cells (CTC) liquid biopsy market. The data is available for the historic period 2011 to 2019.
Competitive Landscape and Middle East and Africa Circulating Tumor Cells (CTC) Liquid Biopsy Market Share Analysis
Middle East and Africa circulating tumor cells (CTC) liquid biopsy market competitive landscape provide details by the competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width, and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company's focus related to circulating tumor cells (CTC) liquid biopsy market.
The major companies which are dealing in the circulating tumor cells (CTC) liquid biopsy market are Eurofins Genomics ( a subsidiary of Eurofins Scientific), MDx Health, Guardant Health, IMMUCOR, Thermo Fisher Scientific, Inc., Menarini Silicon Biosystems, QIAGEN, Exact Sciences Corporation, Myriad Genetics, Inc., LungLife AI, Inc., Bio-Rad Laboratories, Inc., Illumina, Inc. , Natera Inc., ExoDx ( a subsidiary of Bio-Techne Corporation), Biocept, Inc., F. Hoffman-La Roche Ltd. ,FOUNDATION MEDICINE, INC., Lucence Health, Inc., Inivata Ltd, Biolidics Limited, Vortex Biosciences among others.
For instance,
- في أغسطس 2021، أعلنت شركة Exact Sciences Corporation عن أداء اختبار خزعة سائل الكبد Oncogurard الذي يوفر حساسية بنسبة 82% في المرحلة المبكرة ودقة بنسبة 87%. سيساعد هذا الشركة على المضي قدمًا في العمل على هزيمة السرطان من خلال الكشف المبكر.
تعمل التعاونات والمشاريع المشتركة والاستراتيجيات الأخرى من قبل اللاعب في السوق على تعزيز سوق الشركة في سوق خزعة السائل للخلايا السرطانية المتداولة (CTC)، مما يوفر أيضًا فائدة للمنظمة لتحسين عروضها لسوق خزعة السائل للخلايا السرطانية المتداولة (CTC).
SKU-
احصل على إمكانية الوصول عبر الإنترنت إلى التقرير الخاص بأول سحابة استخبارات سوقية في العالم
- لوحة معلومات تحليل البيانات التفاعلية
- لوحة معلومات تحليل الشركة للفرص ذات إمكانات النمو العالية
- إمكانية وصول محلل الأبحاث للتخصيص والاستعلامات
- تحليل المنافسين باستخدام لوحة معلومات تفاعلية
- آخر الأخبار والتحديثات وتحليل الاتجاهات
- استغل قوة تحليل المعايير لتتبع المنافسين بشكل شامل
Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MIDDLE EAST & AFRICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TECHNOLOGY LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTERS FIVE FORCES
5 REGULATIONS: MIDDLE EAST & AFRICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET
5.1 ROLE OF FDA
5.2 ROLE OF CDC AND HCFA
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 HIGH PREVALENCE OF CANCER
6.1.2 ADVANTAGES OF LIQUID BIOPSY OVER SURGICAL BIOPSY
6.1.3 GOVERNMENT INITIATIVES TO SPREAD AWARENESS ABOUT EARLY DIAGNOSIS OF CANCER
6.1.4 RISE IN FDA APPROVAL
6.1.5 HEALTHCARE REIMBURSEMENT FOR LIQUID BIOPSY
6.2 RESTRAINTS
6.2.1 DOWNSIDES OF LIQUID BIOPSY
6.2.2 RAPID DEVELOPMENT OF ULTRASENSITIVE IMAGING TECHNOLOGIES SUCH AS MAGNETIC RESONANCE IMAGING
6.3 OPPORTUNITIES
6.3.1 STRATEGIC INITIATIVES BY THE MARKET PLAYERS
6.3.2 RISE IN HEALTHCARE EXPENDITURE AND DISPOSABLE INCOME
6.3.3 INCREASE IN RESEARCH AND DEVELOPMENT ACTIVITIES
6.3.4 HUGE MARKET POTENTIAL IN DEVELOPING COUNTRIES
6.4 CHALLENGES
6.4.1 SHORTAGE OF SKILLED PERSONNEL
6.4.2 LACK OF ACCESSIBILITY
7 COVID-19 IMPACT ON MIDDLE EAST & AFRICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET
7.1 IMPACT ON PRICE
7.2 IMPACT ON DEMAND
7.3 IMPACT ON SUPPLY
7.4 KEY INITIATIVES BY MARKET PLAYER DURING COVID 19
7.5 CONCLUSION:
8 MIDDLE EAST & AFRICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY TECHNOLOGY
8.1 OVERVIEW
8.2 CTC DETECTION METHODS
8.3 CTC ENRICHMENT METHODS
8.4 EX VIVO POSITIVE SELECTION
8.5 MOLECULAR (RNA)-BASED TECHNOLOGIES
8.6 FUNCTIONAL IN VITRO CELL INVASION ASSAY
8.7 XENOTRANSPLANTATION MODELS
8.8 MICROCHIPS
8.9 SINGLE SPIRAL MICROCHANNEL
8.1 NEGATIVE SELECTION
8.11 IMMUNOCYTOCHEMICAL TECHNOLOGIES
9 MIDDLE EAST & AFRICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY APPLICATION
9.1 OVERVIEW
9.2 CANCER STEM CELL RESEARCH
9.3 MULTIPLE CHROMOSOME ABNORMALITIES
9.4 OTHERS
10 MIDDLE EAST & AFRICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY END USER
10.1 OVERVIEW
10.2 RESEARCH & ACADEMIC INSTITUTES
10.3 REFERENCE LABORATORIES
10.4 HOSPITALS AND PHYSICIAN LABORATORIES
11 MIDDLE EAST & AFRICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY REGION
11.1 MIDDLE EAST AND AFRICA
11.1.1 SOUTH AFRICA
11.1.2 SAUDI ARABIA
11.1.3 U.A.E
11.1.4 EGYPT
11.1.5 ISRAEL
11.1.6 REST OF MIDDLE EAST AND AFRICA
12 MIDDLE EAST & AFRICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: COMPANY LANDSCAPE
12.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA
13 SWOT ANALYSIS
14 COMPANY PROFILE
14.1 GUARDANT HEALTH
14.1.1 COMPANY SNAPSHOT
14.1.2 REVENUE ANALYSIS
14.1.3 COMPANY SHARE ANALYSIS
14.1.4 PRODUCT PORTFOLIO
14.1.5 RECENT DEVELOPMENTS
14.2 EUROFINS GENOMICS (A SUBSIDIARY OF EUROFINS SCIENTIFIC)
14.2.1 COMPANY SNAPSHOT
14.2.2 REVENUE ANALYSIS
14.2.3 COMPANY SHARE ANALYSIS
14.2.4 PRODUCT PORTFOLIO
14.2.5 RECENT DEVELOPMENTS
14.3 FOUNDATION MEDICINE, INC.
14.3.1 COMPANY SNAPSHOT
14.3.2 COMPANY SHARE ANALYSIS
14.3.3 PRODUCT PORTFOLIO
14.3.4 RECENT DEVELOPMENTS
14.4 ILLUMINA, INC.
14.4.1 COMPANY SNAPSHOT
14.4.2 REVENUE ANALYSIS
14.4.3 COMPANY SHARE ANALYSIS
14.4.4 PRODUCT PORTFOLIO
14.4.5 RECENT DEVELOPMENT
14.5 NATERA, INC.
14.5.1 COMPANY SNAPSHOT
14.5.2 REVENUE ANALYSIS
14.5.3 COMPANY SHARE ANALYSIS
14.5.4 PRODUCT PORTFOLIO
14.5.5 RECENT DEVELOPMENT
14.6 BIO-RAD LABORATORIES, INC.
14.6.1 COMPANY SNAPSHOT
14.6.2 REVENUE ANALYSIS
14.6.3 PRODUCT PORTFOLIO
14.6.4 RECENT DEVELOPMENT
14.7 QIAGEN
14.7.1 COMPANY SNAPSHOT
14.7.2 REVENUE ANALYSIS
14.7.3 PRODUCT PORTFOLIO
14.7.4 RECENT DEVELOPMENTS
14.8 THERMO FISHER SCIENTIFIC INC.
14.8.1 COMPANY SNAPSHOT
14.8.2 REVENUE ANALYSIS
14.8.3 PRODUCT PORTFOLIO
14.8.4 RECENT DEVELOPMENTS
14.9 BIOCEPT, INC.
14.9.1 COMPANY SNAPSHOT
14.9.2 REVENUE ANALYSIS
14.9.3 PRODUCT PORTFOLIO
14.9.4 RECENT DEVELOPMENT
14.1 BIOLIDICS LIMITED
14.10.1 COMPANY SNAPSHOT
14.10.2 REVENUE ANALYSIS
14.10.3 PRODUCT PORTFOLIO
14.10.4 RECENT DEVELOPMENTS
14.11 EXACT SCIENCES CORPORATION
14.11.1 COMPANY SNAPSHOT
14.11.2 REVENUE ANALYSIS
14.11.3 PRODUCT PORTFOLIO
14.11.4 RECENT DEVELOPMENT
14.12 EXODX (A SUBSIDIARY OF BIO-TECHNE CORPORATION)
14.12.1 COMPANY SNAPSHOT
14.12.2 REVENUE ANALYSIS
14.12.3 PRODUCT PORTFOLIO
14.12.4 RECENT DEVELOPMENTS
14.13 F. HOFFMANN-LA ROCHE LTD
14.13.1 COMPANY SNAPSHOT
14.13.2 RECENT FINANCIALS
14.13.3 PRODUCT PORTFOLIO
14.13.4 RECENT DEVELOPMENTS
14.14 IMMUCOR
14.14.1 COMPANY SNAPSHOT
14.14.2 PRODUCT PORTFOLIO
14.14.3 RECENT DEVELOPMENTS
14.15 INIVATA LTD
14.15.1 COMPANY SNAPSHOT
14.15.2 PRODUCT PORTFOLIO
14.15.3 RECENT DEVELOPMENTS
14.16 LUCENCE HEALTH, INC.
14.16.1 COMPANY SNAPSHOT
14.16.2 PRODUCT PORTFOLIO
14.16.3 RECENT DEVELOPMENTS
14.17 LUNGLIFE AI, INC.
14.17.1 COMPANY SNAPSHOT
14.17.2 PRODUCT PORTFOLIO
14.17.3 RECENT DEVELOPMENTS
14.18 MDXHEALTH
14.18.1 COMPANY SNAPSHOT
14.18.2 REVENUE ANALYSIS
14.18.3 PRODUCT PORTFOLIO
14.18.4 RECENT DEVELOPMENT
14.19 MENARINI SILICON BIOSYSTEMS
14.19.1 COMPANY SNAPSHOT
14.19.2 PRODUCT PORTFOLIO
14.19.3 RECENT DEVELOPMENTS
14.2 MYRIAD GENETICS, INC.
14.20.1 COMPANY SNAPSHOT
14.20.2 REVENUE ANALYSIS
14.20.3 PRODUCT PORTFOLIO
14.20.4 RECENT DEVELOPMENTS
14.21 VORTEX BIOSCIENCES
14.21.1 COMPANY SNAPSHOT
14.21.2 PRODUCT PORTFOLIO
14.21.3 RECENT DEVELOPMENTS
15 QUESTIONNAIRE
16 RELATED REPORTS
List of Table
TABLE 1 MIDDLE EAST & AFRICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 2 MIDDLE EAST & AFRICA CTC DETECTION METHODS IN CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 3 MIDDLE EAST & AFRICA CTC ENRICHMENT METHODS IN CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 4 MIDDLE EAST & AFRICA EX VIVO POSITIVE SELECTION IN CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 5 MIDDLE EAST & AFRICA MOLECULAR (RNA)-BASED TECHNOLOGIES IN CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 6 MIDDLE EAST & AFRICA FUNCTIONAL IN VITRO CELL INVASION ASSAY IN CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 7 MIDDLE EAST & AFRICA XENOTRANSPLANTATION MODELS IN CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 8 MIDDLE EAST & AFRICA MICROCHIPS IN CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 9 MIDDLE EAST & AFRICA SINGLE SPIRAL MICROCHANNEL IN CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 10 MIDDLE EAST & AFRICA NEGATIVE SELECTION IN CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 11 MIDDLE EAST & AFRICA IMMUNOCYTOCHEMICAL TECHNOLOGIES IN CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 12 MIDDLE EAST & AFRICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 13 MIDDLE EAST & AFRICA CANCER STEM CELL RESEARCH IN CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 14 MIDDLE EAST & AFRICA MULTIPLE CHROMOSOME ABNORMALITIES IN CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 15 MIDDLE EAST & AFRICA OTHERS IN CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 16 MIDDLE EAST & AFRICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 17 MIDDLE EAST & AFRICA RESEARCH & ACADEMIC INSTITUTES IN CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 18 MIDDLE EAST & AFRICA REFERENCE LABORATORIES IN CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 19 MIDDLE EAST & AFRICA HOSPITALS AND PHYSICIAN LABORATORIES IN CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 20 MIDDLE EAST AND AFRICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 21 MIDDLE EAST AND AFRICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 22 MIDDLE EAST AND AFRICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 23 MIDDLE EAST AND AFRICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 24 SOUTH AFRICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 25 SOUTH AFRICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 26 SOUTH AFRICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 27 SAUDI ARABIA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 28 SAUDI ARABIA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 29 SAUDI ARABIA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 30 U.A.E CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 31 U.A.E CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 32 U.A.E CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 33 EGYPT CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 34 EGYPT CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 35 EGYPT CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 36 ISRAEL CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 37 ISRAEL CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 38 ISRAEL CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 39 REST OF MIDDLE EAST AND AFRICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
List of Figure
FIGURE 1 MIDDLE EAST & AFRICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST & AFRICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST & AFRICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST & AFRICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET : MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST & AFRICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET : COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST & AFRICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST & AFRICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: DBMR MARKET POSITION GRID
FIGURE 8 MIDDLE EAST & AFRICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 9 MIDDLE EAST & AFRICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 MIDDLE EAST & AFRICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: SEGMENTATION
FIGURE 11 THE HIGH PREVALENCE OF CANCER IS EXPECTED TO DRIVE THE MIDDLE EAST & AFRICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 CTC DETECTION METHODS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET IN 2022 & 2029
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE MIDDLE EAST & AFRICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF MIDDLE EAST & AFRICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET
FIGURE 15 PREVALENCE OF BREAST CANCER IN EUROPE, INDIA, AND IN THE U.S.
FIGURE 16 PREVALENCE OF LUNG CANCER IN VARIOUS COUNTRIES, WITH HUNGARY BEING THE HIGHEST PREVALENCE RATE IN WOMEN AND MEN
FIGURE 17 MIDDLE EAST & AFRICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: BY TECHNOLOGY, 2021
FIGURE 18 MIDDLE EAST & AFRICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: BY TECHNOLOGY, 2020-2029 (USD MILLION)
FIGURE 19 MIDDLE EAST & AFRICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: BY TECHNOLOGY, CAGR (2022-2029)
FIGURE 20 MIDDLE EAST & AFRICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: BY TECHNOLOGY, LIFELINE CURVE
FIGURE 21 MIDDLE EAST & AFRICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: BY APPLICATION, 2021
FIGURE 22 MIDDLE EAST & AFRICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: BY APPLICATION, 2020-2029 (USD MILLION)
FIGURE 23 MIDDLE EAST & AFRICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: BY APPLICATION, CAGR (2022-2029)
FIGURE 24 MIDDLE EAST & AFRICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 25 MIDDLE EAST & AFRICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: BY END USER, 2021
FIGURE 26 MIDDLE EAST & AFRICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: BY END USER, 2020-2029 (USD MILLION)
FIGURE 27 MIDDLE EAST & AFRICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: BY END USER, CAGR (2022-2029)
FIGURE 28 MIDDLE EAST & AFRICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: BY END USER, LIFELINE CURVE
FIGURE 29 MIDDLE EAST AND AFRICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: SNAPSHOT (2021)
FIGURE 30 MIDDLE EAST AND AFRICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: BY COUNTRY (2021)
FIGURE 31 MIDDLE EAST AND AFRICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: BY COUNTRY (2022 & 2029)
FIGURE 32 MIDDLE EAST AND AFRICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: BY COUNTRY (2021 & 2029)
FIGURE 33 MIDDLE EAST AND AFRICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: BY TECHNOLOGY (2022-2029)
FIGURE 34 MIDDLE EAST & AFRICA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: COMPANY SHARE 2021 (%)
منهجية البحث
يتم جمع البيانات وتحليل سنة الأساس باستخدام وحدات جمع البيانات ذات أحجام العينات الكبيرة. تتضمن المرحلة الحصول على معلومات السوق أو البيانات ذات الصلة من خلال مصادر واستراتيجيات مختلفة. تتضمن فحص وتخطيط جميع البيانات المكتسبة من الماضي مسبقًا. كما تتضمن فحص التناقضات في المعلومات التي شوهدت عبر مصادر المعلومات المختلفة. يتم تحليل بيانات السوق وتقديرها باستخدام نماذج إحصائية ومتماسكة للسوق. كما أن تحليل حصة السوق وتحليل الاتجاهات الرئيسية هي عوامل النجاح الرئيسية في تقرير السوق. لمعرفة المزيد، يرجى طلب مكالمة محلل أو إرسال استفسارك.
منهجية البحث الرئيسية التي يستخدمها فريق بحث DBMR هي التثليث البيانات والتي تتضمن استخراج البيانات وتحليل تأثير متغيرات البيانات على السوق والتحقق الأولي (من قبل خبراء الصناعة). تتضمن نماذج البيانات شبكة تحديد موقف البائعين، وتحليل خط زمني للسوق، ونظرة عامة على السوق ودليل، وشبكة تحديد موقف الشركة، وتحليل براءات الاختراع، وتحليل التسعير، وتحليل حصة الشركة في السوق، ومعايير القياس، وتحليل حصة البائعين على المستوى العالمي مقابل الإقليمي. لمعرفة المزيد عن منهجية البحث، أرسل استفسارًا للتحدث إلى خبراء الصناعة لدينا.
التخصيص متاح
تعد Data Bridge Market Research رائدة في مجال البحوث التكوينية المتقدمة. ونحن نفخر بخدمة عملائنا الحاليين والجدد بالبيانات والتحليلات التي تتطابق مع هدفهم. ويمكن تخصيص التقرير ليشمل تحليل اتجاه الأسعار للعلامات التجارية المستهدفة وفهم السوق في بلدان إضافية (اطلب قائمة البلدان)، وبيانات نتائج التجارب السريرية، ومراجعة الأدبيات، وتحليل السوق المجدد وقاعدة المنتج. ويمكن تحليل تحليل السوق للمنافسين المستهدفين من التحليل القائم على التكنولوجيا إلى استراتيجيات محفظة السوق. ويمكننا إضافة عدد كبير من المنافسين الذين تحتاج إلى بيانات عنهم بالتنسيق وأسلوب البيانات الذي تبحث عنه. ويمكن لفريق المحللين لدينا أيضًا تزويدك بالبيانات في ملفات Excel الخام أو جداول البيانات المحورية (كتاب الحقائق) أو مساعدتك في إنشاء عروض تقديمية من مجموعات البيانات المتوفرة في التقرير.